We are live on ! Find out more
ADVM

Adverum Biotechnologies
ADVM

Delisted

ADVM was delisted on the 8th of December, 2025.

Back to rankings

116 hedge funds and large institutions have $693M invested in Adverum Biotechnologies in 2019 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 33 increasing their positions, 38 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more call options, than puts

Call options by funds: $13.5M | Put options by funds: $3.69M

160% more capital invested

Capital invested by funds: $267M → $693M (+$426M)

138% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 13

17% more funds holding

Funds holding: 99 → 116 (+17)

1.71% more ownership

Funds ownership: 7.6% → 9.31% (+1.7%)

13% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 38

Holders
116
Holders Change
+17
Holders Change %
+17.17%
% of All Funds
2.29%
Holding in Top 10
6
Holding in Top 10 Change
+6
Holding in Top 10 Change %
% of All Funds
0.12%
New
31
Increased
33
Reduced
38
Closed
13
Calls
$13.5M
Puts
$3.69M
Net Calls
+$9.85M
Net Calls Change
+$9.28M

Top Buyers

Rank Fund Capital Flow
1
ACP
Acuta Capital Partners
California
+$11.7M
2
ACA
Avoro Capital Advisors
New York
+$8.81M
3
VMI
VHCP Management III
New York
+$8.34M
4
Goldman Sachs
Goldman Sachs
New York
+$5.38M
5
UBS Group
UBS Group
Switzerland
+$4.7M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$15.2M
2
Renaissance Technologies
Renaissance Technologies
New York
-$10.9M
3
SSA
Schonfeld Strategic Advisors
New York
-$5.18M
4
Citadel Advisors
Citadel Advisors
Florida
-$5.08M
5
Primecap Management
Primecap Management
California
-$2.48M
Name Holding Trade Value Shares
Change 		Change in
Stake
VMI
26
VHCP Management II
New York
$4.42M +$3.38M +38,362 New
SCM
27
Soleus Capital Management
Connecticut
$3.95M +$3.02M +34,280 New
Charles Schwab
28
Charles Schwab
California
$3.79M +$68.6K +778 +2%
FM
29
Frazier Management
Washington
$3.09M +$2.37M +26,834 New
Allianz Asset Management
30
Allianz Asset Management
Germany
$3.07M +$1.73M +19,649 +279%
Citadel Advisors
31
Citadel Advisors
Florida
$3.04M -$5.08M -57,676 -69%
UBS AM
32
UBS AM
Illinois
$3.04M +$2.33M +26,390 New
Wellington Management Group
33
Wellington Management Group
Massachusetts
$2.79M +$2.14M +24,261 New
Bank of New York Mellon
34
Bank of New York Mellon
New York
$2.75M +$408K +4,629 +24%
CAC
35
Cowen and Company
New York
$2.73M +$2.09M +23,658 New
Deutsche Bank
36
Deutsche Bank
Germany
$2.53M +$1.18M +13,380 +156%
N
37
Nuveen
North Carolina
$2.48M +$36.7K +416 +2%
ECM
38
Endurant Capital Management
California
$2.48M +$1.89M +21,482 New
Wells Fargo
39
Wells Fargo
California
$2.47M +$1.65M +18,703 +680%
DM
40
Deerfield Management
New York
$2.44M +$1.86M +21,134 New
CS
41
Candriam SCA
Luxembourg
$2.3M +$1.76M +20,000 New
D.E. Shaw & Co
42
D.E. Shaw & Co
New York
$2.2M -$337K -3,827 -17%
Norges Bank
43
Norges Bank
Norway
$2.01M -$626K -7,099 -29%
Invesco
44
Invesco
Georgia
$1.93M +$1,000K +11,345 +209%
BNP Paribas Financial Markets
45
BNP Paribas Financial Markets
France
$1.85M +$1.34M +15,162 +1,757%
PP
46
PDT Partners
New York
$1.59M +$1.22M +13,820 New
Jacobs Levy Equity Management
47
Jacobs Levy Equity Management
New Jersey
$1.43M +$630K +7,144 +135%
California Public Employees Retirement System
48
California Public Employees Retirement System
California
$1.43M -$88.9K -1,009 -8%
Squarepoint
49
Squarepoint
New York
$1.29M -$782K -8,870 -44%
Walleye Capital
50
Walleye Capital
New York
$1.26M +$701K +7,952 +267%
1
2
3 4 5

ADVM Hedge Fund Activity: Q4 2019 in Review

116 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q4 2019, worth a combined $693M — up 160% from $267M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new ADVM positions and 13 closed out — a net gain of 18 holders — while 33 added to existing stakes and 38 trimmed.

The largest buyer was Acuta Capital Partners, opening a new position worth an estimated $11.7M. The largest seller was State Street, cutting an estimated $15.2M.

  • 116 institutional investors held Adverum Biotechnologies (ADVM) as of Q4 2019, up from 99 in Q3 2019.
  • Funds reported $693M of Adverum Biotechnologies stock for Q4 2019, up 160% quarter-over-quarter.
  • 31 funds opened new Adverum Biotechnologies positions in Q4 2019 and 13 closed out, a net change of +18 holders.
  • The largest Adverum Biotechnologies buyer in Q4 2019 was Acuta Capital Partners, an estimated $11.7M added.
  • The largest Adverum Biotechnologies seller in Q4 2019 was State Street, an estimated $15.2M sold.

Based on aggregated 13F filings for Q4 2019.